Introduction
Staphylococcus aureus bloodstream infection (BSI) remains an issue of concern not only due to its high attributable mortality but also due to the development of haematogenous complications. 1, 2 Infective endocarditis (IE) represents the most feared complication of S. aureus BSI and occurs in up to 10% of these patients. 2 Some factors related to the underlying diseases and the clinical management of bacteraemia have been proposed as risk factors. 2 High MICs of vancomycin (usually defined by MIC values 1.5 mg/L by Etest, a simple routine test) have been suggested to exert a prognostic role in MRSA BSI, although contradictory results have been published. [3] [4] [5] [6] [7] [8] These contradictory results might have been due to the use of crude mortality as primary outcome and the fact that these studies were performed on cohorts of patients with S. aureus BSI from different sources (both low risk and high risk). In fact, a multicentre study performed by the Spanish Network for Research in Infectious Diseases (REIPI) that included episodes of MRSA BSI from different sources failed to demonstrate a significant association between high MIC values of vancomycin and various outcome measures, such as all-cause mortality and haematogenous seeding, including IE. 5, 9, 10 We postulated that the selection of a more homogeneous and similarly handled patient population such as those with MRSA catheter-related (CR)-BSI could better detect a potential role of high vancomycin MIC values in ultimately identifying subjects at increased odds of developing IE. We therefore performed a subanalysis of the REIPI MRSA BSI cohort restricted to the group of patients diagnosed with CR-BSI.
Materials and methods

Study design and setting
This study was conducted from June 2008 to December 2009 in 21 Spanish hospitals (4 with ,500 beds, 9 with 500-1000 beds and 8 with .1000 beds), as detailed elsewhere.
5,9,10 An infectious disease (ID) specialist prospectively followed-up adult patients (16 years old) with MRSA identified from blood cultures at the local microbiology laboratory until discharge or in-hospital death. In addition, the post-discharge occurrence of IE, other MRSA-attributable complications or death was monitored up to at least 30 days after BSI onset through review of medical records in order to ensure that subsequent events leading to hospital readmission were actively captured. Those that did not meet the inclusion criteria (signs and symptoms consistent with sepsis) were excluded. A standardized case report form with demographic and clinical information was applied. Strains were sent to a central laboratory for further studies. Only the first isolate of each episode of MRSA BSI was considered for the global analysis and those patients diagnosed with CR-BSI were included in the present sub-analysis. The primary study outcome was the subsequent development of IE. We also analysed as secondary outcomes all-cause mortality rates within the first 48 h and 30 days from the first blood culture yielding MRSA (early and late mortality, respectively).
Ethics
The study protocol was approved by the REIPI and the local institutional ethics committees of each participating centre. Because no direct patient contact was planned, the requirement for informed consent was waived. All data were locally anonymized and only then transferred for analysis.
Study definitions
High vancomycin MIC (our main predictor variable) was a priori defined as an MIC value 1.5 mg/L determined by Etest. This interpretative cut-off value was selected on the basis of previous literature.
8,11 Additionally, we also explored an alternative threshold (1.0 mg/L) for MIC values obtained by the broth microdilution (BMD) method. MRSA BSI was defined as the presence of at least one positive blood culture for MRSA in a sample from a patient with clinical findings consistent with infection. The diagnosis of CR-BSI as the primary source of BSI was concluded by two independent ID clinical researchers following CDC criteria. 12 Initial antibiotic therapy was defined as that administered within the first 48 h from the onset of CR-BSI. Definitive treatment was that administered once the results of antimicrobial susceptibility testing become available. Therapy was deemed appropriate when the MRSA isolate was susceptible to at least one of the antibiotics administered according to the clinical breakpoints proposed by the CLSI, with the exception of aminoglycosides (which were always considered inappropriate regardless of the in vitro susceptibility pattern of the isolate). Early vascular catheter removal denoted the removal of all the vascular accesses within the first 48 h. Haematogenous complication was defined as the presence of a focal infection (IE, septic arthritis or vertebral osteomyelitis) caused by haematogenous seeding from the vascular catheter that was deemed to act as the portal of entry. IE complicating CR-BSI was diagnosed in cases that met modified Duke criteria 13 at least 24 h after the onset of the BSI (i.e. the calendar date on which the first blood cultures positive for MRSA were drawn). Persistent BSI was defined by the growth of MRSA in blood cultures after .48 h of appropriate antibiotic therapy. 14 All clinical data were interpreted in accordance with the ID specialist criteria. The main variables recorded included age, site of acquisition (nosocomial ICU, nosocomial non-ICU, haemodialysis units, and other forms of healthcare-associated acquisition according to the definition proposed by Friedman et al. ), therapeutic measures administered, and 30 day outcome. Early mortality was considered when the patient died within the first 48 h after the diagnosis of MRSA-BSI, whereas late mortality denoted the occurrence of death beyond that point.
Microbiological methods
Each local laboratory identified the MRSA isolates and performed preliminary susceptibility testing. Further analysis was carried out in a central laboratory for all isolates. Microbiological identification was confirmed by latex agglutination (Pastorex Staph-plus, Bio-Rad Laboratories, Madrid, Spain) and DNase production (DNasEtest Agar, bioMérieux, Marcy l' Etoile, France), whereas antimicrobial susceptibility testing was performed by the BMD method using commercial panels (ESTEN 2009, Sensititre TM , Izasa, Barcelona, Spain) read visually, with results interpreted following the CLSI guidelines. Specifically, MIC values of vancomycin were also assessed by Etest (bioMérieux, Marcy l' Etoile, France) on Mueller-Hinton agar seeded with bacteria from a stock with turbidity equal to that of a 0.5 McFarland standard. 19 PFGE was performed after SmaI restriction of chromosomal DNA following a previously published method. 20 Restriction patterns were interpreted following the criteria published elsewhere. 21 All available isolates were studied by PFGE and agr typing. Multilocus sequence type (MLST) 22 and the staphylococcal chromosome cassette mec (SCCmec) types 23 were studied in a subset of representative isolates that included all PFGE types and subtypes and all antibiotic resistance phenotypes. MLSTs and SCCmec types were further inferred for strains with identical genotype and phenotype. MLST sequences types were assigned through the MLST database (http://www.mlst.net), and clonal complexes (CC) were defined using the EBURST v. 3 algorithm (http://eburst.mlst.net). The agr polymorphism and the presence of genes encoding Panton-Valentin leucocidin [class S and F proteins (lukS-PV and lukF-PV)] were examined by PCR following previously described methodology.
24,25
Statistical analysis
Quantitative data were shown as the mean + SD or the median with IQRs. Qualitative variables were expressed as absolute and relative frequencies. Student's unpaired t-test was used to compare normally distributed continuous variables, the Mann-Whitney U-test to compare non-normally distributed continuous variables, and the v 2 test and Fisher's exact test to compare proportions, as appropriate. To assess the effect of the vancomycin MICs of the MRSA isolate (main predictor) and other variables on the subsequent development of IE, Kaplan-Meier event-free survival curves were plotted and comparison between groups was performed by means of the log-rank test.
It is conventionally assumed that logistic models should be used with a minimum of 10 events per predictor variable, since the resulting models High vancomycin MICs and endocarditis in MRSA CR-BSI JAC might be affected by increasing bias and variability, unreliable confidence interval coverage and convergence problems as this ratio declines below such a threshold. 26 Therefore, and due to the relatively low number of cases of IE in our cohort, we could not assess by a single multivariate model the potential impact on the primary outcome of high MIC values of vancomycin. We alternatively performed an exploratory approach by constructing different backward stepwise Cox proportional hazards models in which the effect of the predictor variable of interest was adjusted for those variables found to be statistically significant at the univariate level (P , 0.10) and/or those considered clinically relevant. Associations were expressed as HR with 95% CIs.
All statistical tests were two-tailed and the threshold of statistical significance was set at a P value ,0.05. The statistical software SPSS v. 21.0 was used for statistical analysis, whereas graphics were generated with Prism v. 6.0 (GraphPad Software Inc., La Jolla, CA, USA). Variables with .30% of missing values were excluded from the final analysis.
Results
Clinical characteristics and outcomes
Out of 579 episodes of MRSA BSI included in the overall REIPI cohort, a vascular catheter was concluded to be the primary source of infection in 218 cases (37.7%). MRSA strains were not available for analysis in 11 of these cases. Therefore, 207 episodes of MRSA CR-BSI (occurring in the same number of patients) were finally included for analysis in the present study.
The main clinical characteristics of the study cohort are shown in Table 1 . Median follow-up period from the onset of the first episode of CR-BSI was 41 days (IQR 20-59). Early catheter withdrawal was performed in 174 episodes (84.1%), whereas initial therapy was appropriate in 158 (76.3%). This therapeutic regimen included vancomycin in 99 patients (47.8%), daptomycin in 25 (12.1%) and linezolid in 18 (8.7%). In 49 patients (23.7%) no empirical antibiotics or non-effective antibiotics against MRSA were initially administered. The median duration of antibiotic therapy was 17 days (IQR 14-22), with longer therapies for patients diagnosed with IE (32.9 versus 18.9 days; P " 0.003).
Overall, 41 patients (19.8%) developed some form of haematogenous complication. In detail, IE was diagnosed in 10 patients (4.8%) whose clinical characteristics are detailed in Table S1 (available as Supplementary data at JAC Online). Early and late mortality rates were 3.4% and 25.1%, respectively.
Clinical correlations of MIC values and molecular characteristics of MRSA strains
High vancomycin MICs were observed in 97 (46.9%) and 44 (21.3%) strains when susceptibility was tested by means of the Etest and BMD methods, respectively. A comparison of the results of susceptibility testing between patients with or without IE is shown in Table 2 . The geometric mean of vancomycin MIC values by Etest was significantly higher among MRSA isolates in patients that developed IE (1.48+0.23 versus 1.16+0.45 mg/L; P " 0.033). The corresponding MIC ranges were 1.00-2.00 and 0.38-3.00 mg/L for isolates from patients with and without IE, respectively. In accordance with this, 90.0% (9/10) of isolates obtained from episodes of CR-BSI complicated by IE exhibited high MICs of vancomycin, compared with 44.7% (88/197) in the remaining cohort (P " 0.007). On the contrary, no significant differences between both groups were found when vancomycin susceptibility testing was performed by BMD irrespective of whether MIC values were analysed as a continuous variable or dichotomized (,1.0 versus 1.0 mg/L). Table 1 shows comparative clinical characteristics of patients according to Etest MIC values of vancomycin. The rate of IE complicating MRSA CR-BSI was significantly higher in cases due to strains with high MIC values [9.3% (9/97) versus 0.9% (1/110); P " 0.01]. As depicted in Figure 1 , the Kaplan-Meier survival curve estimation showed that episodes due to isolates with vancomycin MIC values 1.5 mg/L had a significantly lower probability of remaining free from IE at the end of the first year of follow-up (57.0% versus 98.0%; P " 0.009). On the other hand, no significant differences regarding agr type, CC, MLST sequence type, PFGE type or the presence of Panton-Valentine leucocidin were found between MRSA isolates obtained from patients with or without IE (Table S2) . Finally, the presence of high MICs of vancomycin was not associated with higher rates of severe sepsis, higher Pitt scores, or increased early or late mortality rates (Table 1) .
Risk factors for the development of IE
Comparison between patients with or without IE following MRSA CR-BSI is detailed in Table 3 , whereas univariate Cox regression analysis of the risk factors for the development of this complication is shown in Table 4 . Patients developing IE had lower comorbidity burden (as measured by the Charlson index) and were more likely to have been admitted to an acute care hospital within the prior months and to have a non-fatal underlying condition. Different Cox models including a maximum of two variables at a time were constructed to adjust the role of high vancomycin MIC values (1.5 mg/L by Etest) for the confounding effect of these and other relevant covariates (i.e. appropriateness of initial therapy or early catheter removal). As shown in Figure 2 , the presence of decreased susceptibility to vancomycin in the causative MRSA isolate was kept as an independent risk factor for the development of IE in all these exploratory models (minimum adjusted HR 9.18; 95% CI 1.16-72.78; P " 0.036).
Discussion
The aim of this study was to investigate the potential relationship between vancomycin susceptibility and risk of IE in a subgroup of patients from the REIPI cohort diagnosed with MRSA CR-BSI. Approximately 5% of these patients developed IE, an incidence comparable to that found in previous series. 2, [27] [28] [29] In all but one of these episodes the causative isolate had elevated MICs of vancomycin (1.5 mg/L) when testing was performed by Etest. In line with similar studies conducted in Spain, 7,30 the overall prevalence of strains with decreased susceptibility to vancomycin according to this method was high (46.9%). Interestingly, patients who remained free from IE during the follow-up were less likely to have been infected with one of these isolates. This association remained consistent across various exploratory models, revealing that CR-BSI episodes due to strains of MRSA with high vancomycin MIC exhibited an 10-fold increased risk of being subsequently complicated by IE.
There is an ongoing controversy regarding the real prognostic significance of the finding of vancomycin MIC values that are elevated (but still within the range of susceptibility) among MRSA San-Juan et al.
isolates, particularly when all-cause mortality is used as the main study outcome. A meta-analysis found an increased risk of mortality and treatment failure among patients with serious MRSA infections due to strains with high vancomycin MIC values. 11 On the contrary, the more recent meta-analysis by Kalil et al.,
8 which summarized data from over 8000 episodes of S. aureus BSI, failed to demonstrate such an association, regardless of the method used for testing (Etest or BMD). In the present cohort, focused on patients with a low-risk source of infection, we were unable to confirm a correlation between vancomycin MICs and either early or late mortality rates; however, we have previously shown that the presence of a decreased susceptibility to vancomycin in patients with methicillin-susceptible S. aureus CR-BSI favours the development of septic thrombophlebitis and persistent bacteraemia. [31] [32] [33] Data from this study support that the presence of a decreased susceptibility to vancomycin could be a surrogate marker of increased pathogenicity or vascular adhesion also among MRSA strains, which favours the development of IE. 
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The identification in different studies of high vancomycin MIC values as an independent risk factor for persistent MRSA BSI [34] [35] [36] and particularly for IE 37 also provides indirect evidence in this direction. Of note, no relationship between vancomycin MIC values and the risk of haematogenous seeding could be demonstrated in the overall cohort from which the present study was drawn. 10 These apparently contradictory findings may be explained by the fact that our sub-analysis was restricted to patients with CR-BSI, a group that was more homogeneous in terms of severity of underlying conditions, feasibility of source control (i.e. catheter removal), therapeutic approach and expected prognosis than the overall cohort, which rather comprised a mixed group of patients with highrisk (i.e. lower respiratory tract) and low-risk sources of BSI (i.e. skin and soft tissues). Thus, the relative contribution of pathogenrelated factors to the outcome in the overall cohort might have been outweighed by the role of host characteristics or therapyrelated variables, whereas by exclusively focusing on episodes of CR-BSI we aimed at minimizing such clinical confounders.
The biological rationale to explain the increased predisposition to endovascular complications in episodes of BSI due to these strains is not evident. Isolates with decreased susceptibility to vancomycin exhibit certain structural modifications, such as an increased cell wall thickness, 36, 38, 39 that might promote the exposition of some components (i.e. teichoic acids) that would in turn favour specific interaction with host endothelial cells. 40 Impaired intracellular killing by phagocytes has been demonstrated among S. aureus isolates with reduced susceptibility to vancomycin and a thicker wall cell, 38 ,41 a mechanism that may also lead to local endovascular perpetuation. Finally, high vancomycin MICs may arise from prolonged exposure to sublethal levels of this agent, a circumstance that has been found to be associated with an increased capacity for biofilm formation probably through upregulation of a major regulatory locus called staphylococcal accessory regulator A (sarA). 42, 43 Such particular endovascular pathogenicity could pose a common pathogen-related risk factor for the development of both CR-BSI or endovascular complications such as IE.
Some limitations of the present study deserve specific consideration. Concerns regarding the reproducibility of Etest results for measuring vancomycin susceptibility in S. aureus isolates are well described, 44 and therefore this methodological issue should be taken into account when interpreting our results. Since the present study is a subanalysis of an observational cohort, diagnostic workup and clinical management of episodes of complicated bacteraemia depended on the criteria of the attending physician and, therefore, were not necessarily homogeneous across participating centres (i.e. decision on performing echocardiography examination). In this regard, it should be noted that all local researchers were ID specialists with experience in dealing with MRSA BSI and, therefore, a reasonable degree of compliance with clinical practice guidelines issued at that point may be assumed. However, a specific analysis on guidelines adherence in each individual case would have been advisable to ascertain consistency in the management of CR-BSI. Underestimation of the true incidence of IE complicating MRSA CR-BSI may have occurred due to the characteristics of the study. Indeed, the higher than expected mortality rate among patients with IE (70.0%), a dismal outcome that could have been conditioned by the low rate of surgery among this San-Juan et al.
group, would suggest that diagnosis could be biased towards more severe cases. Although the majority of the cases of IE due to MRSA should be clinically evident, the possibility that some incipient cases could have been medically treated with prolonged antibiotic therapy cannot be definitely ruled out, raising the potential for some level of underdiagnosis. In addition, post-discharge follow-up after the index hospitalization was based on review of clinical records, and therefore patients with late-onset IE that were not admitted at the original centre could have been missed by this approach, although this bias seems unlikely due to the organizational structure of the Spanish public health system. Additionally, some specific variables regarding the management of CR-BSI episodes with potential impact on the risk of haematogenous complication (i.e. type and number of vascular catheters) were lacking. Finally, the limited number of events of IE prevented us from performing a single multivariate model in which the role of vancomycin susceptibility was adjusted for all the potentially relevant covariates, although an attempt was made to overcome this circumstance by constructing a number of different exploratory models. Thus, our study should be considered as hypothesis generating rather than definitive, and pending confirmation in a larger international database on MRSA BSI. In summary, our data suggest that episodes of MRSA CR-BSI due to strains with vancomycin MIC values by Etest of 1.5 mg/L are more prone to be complicated by the subsequent development of IE. Therefore, it would be advisable to perform a careful diagnostic work-up to rule out such complication and, eventually, to prolong the duration of antistaphylococcal regimens in this subgroup of high-risk patients. 
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